HHS would review brand-name drugs at least yearly and could label some prices “excessive,” including by comparing them to prices in five other countries. If a drug is deemed excessively priced, the bill would end certain exclusivity protections and require open licensing so other manufacturers can compete while paying royalties. It also adds public reporting, a database, and civil penalties for noncompliance.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Prescription Drug Price Relief Act of 2025 is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Latest action on H.R. 3546: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who this affects: The bill most directly affects brand-name drug manufacturers whose products could be reviewed and labeled excessively priced, which can trigger loss of exclusivity protections and open licensing. It also affects generic and biosimilar manufacturers that could use those open, non-exclusive licenses to enter the market sooner, while paying royalties and meeting price-related conditions. Patients, insurers, and public programs could be affected if additional competition lowers prices for drugs that receive an excessive-price finding. HHS and FDA would take on specific review, licensing, enforcement, and accelerated application deadlines, and NIH would receive funding from certain civil penalties collected under the reporting rules.
Why this matters: This bill matters because it would create a federal system for identifying brand-name drugs with “excessive” prices and then using open licensing to bring in competitors sooner. That could change what patients, insurers, and public programs pay for certain medicines, especially when U.S. prices exceed prices in the listed reference countries. It also increases transparency by requiring detailed manufacturer reports and by publishing a public database and yearly summaries to Congress. The real-world effects on prices, access, and innovation are not guaranteed by the bill’s text and would depend on how the Secretary applies the standards and how manufacturers respond.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Keep acting on Modern Action
Compare the broader issue and related bills without leaving Modern Action.
